FDA Grants Priority Review to Mercks sBLA for Keytruda Monotherapy for ThirdLine Treatment of Patients with Advanced SCLC

FDA Grants Priority Review to Merck’s sBLA for Keytruda Monotherapy for Third-Line Treatment of Patients with Advanced SCLC

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with advanced small cell lung cancer …

More From BioPortfolio on "FDA Grants Priority Review to Merck’s sBLA for Keytruda Monotherapy for Third-Line Treatment of Patients with Advanced SCLC"